We are working on upgrading our websites and despite our best endeavours have experienced census type calamities for almost a week now. Our apologies, we hope to have all problems resolved by Monday August 15th.


Any AUS or NZ company


Browse Australian listed companies

0-9A B C D E F G H I J K L M N O P Q R S T U V W XY Z

Browse current Australian managed funds

0-9A B C D E F G H I J K L M N O P Q R S T U V W X Y Z



Find any Australian or New Zealand company or fund (dead or alive) by using SEARCH above or go directly to the site:


Click here for free access to this company's:
ASX, Legal & CGT Status

Former (or subsequent) names


Shareholder links

Our website ranking of PXS: rating 5
(5 out of 5)



Computershare, Level 3, 60 Carrington Street, Sydney NSW 2000

Tel : +61 (0)3 9415 4000 or 1300 850 505 (within Australia)
Fax : +61 2 8235 8150
RegistryWebsite RegistryEmail

Company details

ISIN: AU000000PXS5
Address: Unit 2, 10 Rodborough Road, FRENCHS FOREST, NSW, AUSTRALIA, 2086
Tel:  (02) 9454 7200 Fax: (02) 9451 3622

Date first listed: 10/11/2003
Company Secretary: David McGarvey
Sector: Pharmaceuticals & Biotechnology Industry Group: XHJ
Activities: Research, development and commercialisation of human therapeutic products that address chronic respiratory and autoimmune diseases and the development of improved lung function tests

News & Events

Expand this box to read and print

the suspension of trading in the securities of Pharmaxis Ltd (the "Company") will be lifted immediately, following receipt of an announcement regarding Bronchitol


Pharmaxis (ASX: PXS) today announced the Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a Marketing Authorisation for Bronchitol, clearing the way for the product to be used in Europe "for the treatment of cystic fibrosis in adults as an add?on therapy to best standard of care."


company expects to receive definitive notification of the outcome of the reexamination of Bronchitol for the treatment of cystic fibrosis from the European Committee for Medicinal Products for Human Use on the evening of Friday 21 October 2011 (Australian time). The Company therefore anticipates making an announcement concerning the reexamination by 8.30am Monday 24 October 2011. That announcement will have the effect of ending the current voluntary suspension of the Company's shares


the securities of Pharmaxis Ltd (the "Company") will be suspended from quotation immediately, at the request of the Company, pending the release of an announcement

OFX Transferring Money Internationally to Free


Click here for free access to this company's:
ASX, Legal & CGT Status

Your comments

Please read our Terms before viewing comments.


Company Updates

Post your comments here

Please read our Terms before posting comments.
    You can post a comment here about this company

    Please click in the "I'm not a robot" box and enter the word/figures you see in the image that then appears.

    loading Posting your comments. Please wait...



    Click here for free access to this company's:
    ASX, Legal & CGT Status

    Directors' on-market share transactions (last 5)

    rss feeds

    Purchases Sales

    03/05/2021Malcolm McComas500,000$0.087$43,500
    02/12/2016Malcolm McComas200,000$0.271$54,167
    29/09/2016Gary Phillips-400,000$0.277$110,636
    29/10/2013Simon Buckingham200,000$0.124$24,854
    02/05/2013Gary Phillips60,000$0.155$9,300

    Click here for the last 20 transactions all companies

    Directors & Executives (current)

    Malcolm McComasNon Exec Chairman, Independent Director07/04/2003
    Gary PhillipsCEO, Executive Director12/03/2013
    David McGarveyCFO, Company Secretary01/12/2002
    Will DelaatIndependent Director23/06/2008
    Kathleen MettersNon Exec Director07/06/2017
    Neil GrahamNon Exec Director04/05/2020

    Date of first appointment, title may have changed.

    Directors & Executives (former)

    Edward RaynerNon Exec Director17/09/201814/08/2020
    Simon BuckinghamIndependent Director25/07/201222/11/2018
    Richard van den BroekDirector07/04/200919/09/2013
    John VilligerDirector15/11/200619/09/2013
    Alan RobertsonCEO, Director25/07/200012/03/2013
    Denis HanleyChairman, Independent Director24/10/200101/05/2012
    Peter FarrellIndependent Director16/03/200621/10/2009
    Charles KiefelNon Exec Director19/12/2007
    Brigitte SmithNon Exec Director26/10/2006
    Carrie HillyardNon Exec Director11/04/2006
    Brett CharltonExecutive01/06/199820/03/2006

    Date of first appointment, title may have changed.